Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Mental Health Strategy 2024-2030

Executive Summary
 
We can all play a role in promoting and safeguarding mental health for all population groups and in supporting individuals going through difficult times. This strategy serves as a seven-year roadmap aimed at guiding the Ministry of Public Health and all relevant stakeholders while mobilizing efforts to improve mental health in Lebanon. In Lebanon, in particular, improving mental health also requires addressing the social, economic, and political factors that negatively impact mental well-being and hinder the recovery process.
 
The strategy was developed using a comprehensive approach to address key issues. First, an assessment of the mental health situation in the country was conducted, including the burden of diseases, needs, and an evaluation of the existing system’s ability to meet these needs. Previous efforts were also reviewed to identify areas that need to be maintained and those requiring improvement. Furthermore, consultations were held with experts and local stakeholders, including individuals with lived experiences, to help set strategic priorities. The strategy was also guided by international frameworks, including World Health Organization (WHO) guidelines and other evidence-based recommendations. Special care was taken to select approaches that are appropriate and adaptable to the local context. Finally, the strategy was published and made available to the public for feedback and revisions.
 
The strategy addresses all fundamental aspects of the mental health system to enhance overall mental well-being and prevent mental disorders, with a focus on the following key areas:
  • Raising awareness about mental health, reducing misconceptions, and implementing evidence-based interventions to prevent mental health issues. This includes emphasizing the importance of addressing political, social, and economic factors that influence mental health.
  • Empowering individuals by providing them with the resources, knowledge, and skills necessary to protect their mental well-being and ensuring access to available services when needed.
  • Ensuring that individuals with mental health disorders can access high-quality care whenever they need it, regardless of their place of residence.
  • Supporting healthcare providers and all professionals in the field by building their capacity based on evidence-based practices and helping them safeguard their own mental health.
  • Preventing and reducing harmful practices that violate human rights and quality standards in the provision of mental health services.
  • Enhancing data availability and conducting valuable research to guide and support efforts to improve mental health across the country.
  • Establishing legal frameworks, policies, and appropriate funding mechanisms to strengthen the mental health system.
  • Integrating the views, perspectives, and preferences of individuals with lived experiences in the design, development, and implementation of services, policies, and practices.
Specific actions have been planned for each of these key areas to ensure the necessary improvements in the country.
 

 
National Mental Health Strategy 2024-2030 (Please click on this link to download the document)
 
Theory of Change Map (Please click on this link to download the document)

Executive Summary (English, French, Arabic) 
 
    ...
    185
ATC Name B/G Ingredients Dosage Form Price
N02CC01 IMIGRAN B Sumatriptan (succinate) - 50mg 50mg Tablet, film coated 378,964 L.L
A04AD GRAVOL B Dimenhydrinate - 15mg/5ml 15mg/5ml Liquid 258,018 L.L
A10BD15 XIGDUO XR B Metformin HCl XR - 1000mg, Dapagliflozin - 5mg Tablet 3,867,041 L.L
B01AC27 UPTRAVI B Selexipag - 1600mcg 1600mcg Tablet, film coated 275,097,581 L.L
L01XG03 NINLARO B Ixazomib - 4mg 4mg Capsule, hard 388,991,058 L.L
S02AA15 SEPTOCIPRO OTICO B Ciprofloxacine (HCl) - 1mg/0.5ml 1mg/0.5ml Solution 473,033 L.L
A04AD GRAVOL B Dimenhydrinate - 50mg 50mg Tablet 163,949 L.L
C01EB15 VASTAREL B Trimetazidine - 35mg 35mg Tablet, film coated, modified release 1,053,573 L.L
L01CX01 YONDELIS B Trabectedin - 1mg 1mg Injectable powder for solution 126,536,515 L.L
L01XG03 NINLARO B Ixazomib - 3mg 3mg Capsule, hard 348,420,676 L.L
M05BA06 BONDRONAT B Ibandronic acid (monosodium monohydrate) - 6mg/6ml 6mg/6ml Injectable concentrated powder for solution 24,963,868 L.L
A04AD GRAVOL B Dimenhydrinate - 100mg 100mg Suppository 294,302 L.L
C09AA05 TRITACE B Ramipril - 5mg 5mg Tablet 509,316 L.L
D06BA51 IALUGEN PLUS B Silver sulfadiazine - 10mg/g, Sodium hyaluronate - 2mg/g Cream 1,064,323 L.L
J01DI01 ZEVTERA B Ceftobiprole medocaril Sodium - 500mg 500mg Injectable powder for concentrate for solution 47,129,773 L.L
L01XG03 NINLARO B Ixazomib - 2.3mg 2.3mg Capsule, hard 272,619,919 L.L
M05BA06 BONVIVA B Ibandronic acid - 3mg/3ml 3mg/3ml Injectable solution 3,144,591 L.L
R05CB06 MUCOSOLVAN B Ambroxol HCl - 30mg/5ml 30mg/5ml Syrup 380,307 L.L
S02AA30 TYOTOCIN B Hexylresorcinol - 0.1%, Antipyrine - 5%, Benzocaine - 1.25%, Tyrothricin - 0.05% Drops solution 409,552 L.L
C01EB17 PROCORALAN B Ivabradin (HCl) - 5mg 5mg Tablet, film coated 1,890,786 L.L
L01XJ01 ERIVEDGE B Vismodegib - 150mg 150mg Capsule 465,368,012 L.L
A10BD15 XIGDUO XR B Metformin HCl XR - 1000mg, Dapagliflozin - 10mg Tablet 3,006,579 L.L
B01AE07 PRADAXA B Dabigatran etexilate (mesilate) - 110mg 110mg Capsule, hard 1,603,204 L.L
D06BA51 IALUGEN PLUS B Silver sulfadiazine - 10mg/g, Sodium hyaluronate - 0.5mg/g Gauze 1,463,444 L.L
J01DI54 ZERBAXA B Ceftolozane Sulfate - 1g, Tazobactam (sodium) - 0.5g Injectable powder for concentrate for solution 74,780,802 L.L
L01XK01 LYNPARZA B Olaparib - 100mg 100mg Tablet, film coated 230,789,350 L.L
L04AX06 IMNOVID B Pomalidomide - 2mg 2mg Capsule, hard 407,188,707 L.L
N02CC04 MAXALT B Rizatriptan (benzoate) - 10mg Tablet 439,436 L.L
S02CA02 VIOCORTENE B Clioquinol - 10mg/ml, Flumetasone pivalate - 0.2mg/ml Drops 568,253 L.L
A05AA02 URSOFALK B Ursodeoxycholic acid - 250mg 250mg Capsule 2,823,413 L.L
    ...
    185
Sitemap
© Copyrights reserved to Ministry of Public Health 2025